Trade Names:Ferrlecit- Injection 62.5 mg per 5 mL (12.5 mg/mL) of elemental iron
Provides iron to replenish hemoglobin and depleted iron stores.
Treatment of iron deficiency anemia in patients undergoing chronic hemodialysis and supplemental erythropoietin.
All anemias not associated with iron deficiency; evidence of iron overload; hypersensitivity to any component of the product.
Dosage is expressed as mg of elemental iron.Adults
IV Iron Replacement Dose: 10 mL (iron 125 mg) diluted in 100 mL of sodium chloride 0.9%. Infuse over 1 h. Most patients require a minimum cumulative dose of 1 g over 8 sessions at sequential dialysis treatments.Children
IV Iron Replacement Dose: 0.12 mL/kg (elemental iron 1.5 mg/kg) diluted in 25 mL 0.9% sodium chloride and given by IV infusion over 1 h at 8 sequential dialysis sessions (max, 125 mg/dose).
Store ampules at controlled room temperature (59° to 86°F). Protect from freezing. Use immediately after dilution in saline.
May potentiate adverse reactions.Oral iron preparations
May have reduced absorption.
Do not mix with other medications or add to parenteral nutrition solutions.
None well documented.
Hypotension (29%); hypertension (13%); syncope (6%); tachycardia (5%); angina pectoris; bradycardia; MI; pulmonary edema; vasodilation.
Dizziness (13%); fatigue, paresthesia (6%); agitation; malaise; nervousness; somnolence (postmarketing).
Pruritus (6%); increased sweating; rash.
Abnormal vision; conjunctivitis; ear disorder.
Diarrhea, nausea, vomiting (35%); anorexia; dry mouth; dyspepsia; eructation; flatulence; GI disorder; melena; rectal disorder (postmarketing).
Abnormal erythrocytes (11%); anemia; hemorrhage; leukocytosis; lymphadenopathy; sepsis (postmarketing).
Injection-site reactions (33%).
Hyperkalemia (6%); generalized edema (5%); edema; hypervolemia; hypoglycemia; hypokalemia; leg edema; peripheral edema.
Leg cramps (10%); arthralgia; myalgia.
Cramps (25%); chest pain, pain (10%); fever (5%); abscess; arm pain; back pain; chills; flu-like syndrome; hypersensitivity; hypertonia; infection; rigors (postmarketing).
Category B .
Safety and efficacy are not established for children younger than 6 yr of age.
Use with caution, usually starting at the low end of the dosing range because of the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant diseases or other drug therapy.
Rare cases of serious hypersensitivity reported.
This product contains benzyl alcohol and should not be used in premature infants and neonates.
Associated with too rapid administration. Do not exceed 125 mg/h (2.1 mg/min).
Unwarranted therapy with parenteral iron will cause excess storage of iron and possibly cause exogenous hemosiderosis, especially in patients with hemoglobinopathies and other refractory anemias.
Hypotension associated with lightheadedness, malaise, fatigue, weakness, or severe chest, back, flank, or groin pain reported. This reaction has not been associated with hypersensitivity and usually resolves within 1 to 2 h.
Accumulation of iron in iron storage sites, abdominal pain, diarrhea, vomiting, pallor, cyanosis, lassitude, drowsiness, hyperventilation (caused by acidosis), CV collapse.
Copyright © 2009 Wolters Kluwer Health.